Clinical Trials Logo

Endothelial Dysfunction clinical trials

View clinical trials related to Endothelial Dysfunction.

Filter by:

NCT ID: NCT06018480 Recruiting - Clinical trials for Endothelial Dysfunction

The Effect of NADPH Oxidase and Creatine Supplementation on Microvascular Blood Flow Regulation

NOXCROS
Start date: August 29, 2023
Phase: N/A
Study type: Interventional

This research study seeks to determine the effects of an enzyme in the human body called NADPH oxidase (NOX) on blood flow. In addition, the study will investigate the benefits of creatine monohydrate, a common sports performance supplement, on blood food and vessel function. Participants will undergo two study arms, one in which they consume a high carbohydrate meal pre- and post-creatine monohydrate supplementation and one in which they will consume a high carbohydrate meal pre- and post-placebo supplementation. Blood flow and endothelial function will be assessed before and for 4 hours following the consumption of a high-carbohydrate meal pre and post-supplementation (creatine monohydrate and placebo).

NCT ID: NCT05957120 Completed - Inflammation Clinical Trials

Subclinical Impairment of Cardiovascular System in Patients With Psoriasis

PaS
Start date: January 3, 2022
Phase:
Study type: Observational

A cross-sectional study will be conducted, which will include 80 young patients with psoriasis, aged 30-45 years, treated with five different types of antipsoriatic treatment, and 20 healthy patients. All 100 subjects will be subjected to anthropometric measurements, blood will be collected for laboratory tests, and an imaging test will be performed to determine the function of the endothelium and arterial stiffness. The results will then be statistically analyzed.

NCT ID: NCT05939934 Not yet recruiting - Clinical trials for Endothelial Dysfunction

Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal

ORTAP
Start date: September 2023
Phase: N/A
Study type: Interventional

Obstructive sleep apnea hypopnea syndrome (OSAS) is a frequent disease with neuropsychological and cardiovascular (CV) consequences. Continuous positive pressure (CPAP), the main treatment for OSAHS, is effective on the majority of symptoms but restrictive, which can promote non-compliance. Treatment interruptions are often observed in connection with intercurrent events such as nasal obstructions or even when patients are on the move. However, randomized trials have shown that stopping treatment, even for a short time, leads to a recurrence of symptoms and significant CV disturbances (increase in blood pressure, endothelial dysfunction, cardiac repolarization disorders). It seems important to consider strategies that promote therapeutic continuity. The mandibular advancement device (MAD) is an interesting tool in this regard. MAD is as effective as CPAP on symptoms and CV data. The investigators want to assess its effectiveness as a complementary treatment during treatment discontinuation on the main consequences of OSAHS.

NCT ID: NCT05912322 Active, not recruiting - Inflammation Clinical Trials

Evaluation of Black Chokeberry Bio Juice on Blood Pressure Levels and Endothelial Damage

AROBLENDO
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

In Romania, the diseases of the circulatory system account for 59.3% of deaths, representing the main cause of morbidity and mortality. Barriers of current pharmacological treatments materialized in side effects and limited actions on risk factors increase the necessity of finding more effective, multi-target and less toxic therapeutic strategies. Considering the well-known benefits, natural compounds represent a very important source for drug candidates. The latest in vitro and in vivo studies on Aronia melanocarpa (Michx.) Elliott have highlighted its antioxidant, anti-inflammatory, anti-proliferative, anti-atherosclerotic, hypotensive, antiplatelet, lipid and glucose reduction properties, making it an excellent candidate for the prevention and treatment of cardiovascular and metabolic disorders. The aim of this study is to comprehensive evaluate (in vivo) the Aronia melanocarpa bio juice, obtained from Romania on blood pressure levels and endothelial damage.

NCT ID: NCT05906810 Recruiting - Atherosclerosis Clinical Trials

Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Peri-implantitis and Peri-implant Mucositis

Start date: October 5, 2020
Phase: N/A
Study type: Interventional

A double-blind randomized-controlled clinical trial is conducted in order to evaluate the impact of non-surgical periodontal treatment on endothelial dysfunction parameters in subjects with peri-implantitis/peri-implant mucositis and without any cardiovascular disease.

NCT ID: NCT05872139 Completed - Aging Clinical Trials

Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging

Start date: September 23, 2022
Phase: N/A
Study type: Interventional

The primary goal of this intervention is to determine the efficacy of acute mitochondrial-specific antioxidants to improve vascular endothelial function in middle-aged and older (≥45 y) adults who do no perform regular aerobic exercise. In a double-blind, randomized, placebo-controlled crossover design participants with receive both MitoQ and placebo arm of the study. Primary endpoints will include vascular endothelial function assessed by brachial artery flow-mediated dilation and cardiac function assessed via pulse wave analysis. Secondary endpoints will include measures of aortic stiffness assessed by carotid-femoral pulse wave velocity and carotid artery stiffness (e.g. β-stiffness) and elasticity (carotid compliance, distensibility, and Youngs elastic modulus) from ultrasonography.

NCT ID: NCT05857085 Completed - Clinical trials for Diabetes Mellitus, Type 1

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

ENDIS
Start date: December 15, 2021
Phase: Phase 4
Study type: Interventional

The aim of study is impact of additional treatment with new antidiabetic drugs (semaglutide or empagliflozine) compared to control group in T1DM patients - impact on endothelial function measured by FMD and FPF, arterial stiffness - measured by PWV, inflammatory biomarkers, markers of oxidative stress and endothelial progenitor cells (CD 34+/VDRL2, CD 133+/VDRL2) and correlation with glucovariability or time in range, measured with CGM system.

NCT ID: NCT05831644 Completed - Clinical trials for Endothelial Dysfunction

A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes

Start date: April 25, 2023
Phase: Phase 1
Study type: Interventional

This trial is a single-centre, randomized, double-blind, placebo-controlled, 2-way cross-over phase 1b trial evaluating the pharmacodynamic effect of C21 on endothelial dysfunction and safety in subjects with type 2 diabetes mellitus (T2DM).

NCT ID: NCT05815043 Recruiting - Clinical trials for Endothelial Dysfunction

A Comparison of Sodium-Induced Responses by Sex

Start date: December 13, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to explore the influence of biological sex on sodium-induced blood pressure and vascular function responses to variations in sodium intake in African American/Black adults.

NCT ID: NCT05812755 Recruiting - Clinical trials for Endothelial Dysfunction

SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery

SOLSTICE
Start date: May 19, 2023
Phase: Phase 4
Study type: Interventional

The goal of this mechanistic clinical trial is to learn about the effects of medications called soluble guanylyl cyclase stimulators on vascular function and markers of kidney and brain injury in patients having heart surgery. The main questions it aims to answer are: 1. Does soluble guanylyl cyclase stimulation improve blood vessel function compared to placebo? 2. Does soluble guanylyl cyclase stimulation decrease markers of kidney injury and brain injury compared to placebo? Participants will be randomized to a soluble guanylyl cyclase stimulator called vericiguat or placebo, and researchers will compare vascular function and markers of brain and kidney injury to see if vericiguat improves vascular function and reduces markers of injury. This will provide important information to determine the underlying reasons that patients have some kidney and brain function problems after having heart surgery.